case_images: PMC5131445_01
case_images: The photographs the patient before treatment pazopanib
case_images: 13569_2016_61_Fig1_HTML.jpg
case_images: PMC5131445_01_13569_2016_61_Fig1_HTML.jpg
case_images: Fig1
case_images: One month after the initiation of pazopanib, he presented with vitiligo and hair depigmentation (Figs. 1, 2) which are quite common side effects of pazopanib.  
case_images: One month after the start of pazopanib treatment; Patient presented with loss of hair color and vitiligo
case_images: 13569_2016_61_Fig2_HTML.jpg
case_images: PMC5131445_01_13569_2016_61_Fig2_HTML.jpg
case_images: Fig2
case_images: One month after the initiation of pazopanib, he presented with vitiligo and hair depigmentation (Figs. 1, 2) which are quite common side effects of pazopanib.  
case_images: Patient CT scans; a before initial treatment of tamoxifen; axial plan CT scan performed in September 2013 demonstrates 2.89 cm diameter homogeneous mass located at the left anterior pararenal space of the retroperitoneal area (yellow arrow). b Post contrast CT images in december 2013; retroperitoneal mass (diameter 4.14 cm) progressed after treatment of tamoxifen (yellow arrow). c 9 months after the initiation of pazopanib treatment; the residual mass regressed on CT scan at same level (yellow arrow). d Post contrast CT images obtained in October 2015 showing complete response of the residual mass at 22 months of pazopanib treatment.(yellow arrow)
case_images: 13569_2016_61_Fig3_HTML.jpg
case_images: PMC5131445_01_13569_2016_61_Fig3_HTML.jpg
case_images: Fig3
case_images: After 3 months on tamoxifen, progressive disease was detected by CT scan (Fig. 3a, b). On the follow-up period, first response to treatment was documented 4 months after the initiation of treatment (Fig. 3c). The response to treatment lasted on the follow-up visits, and after 22 months on pazopanib; complete response was achieved on patient's last scan (Fig. 3d).